Rare Disease CROs

Global leader in drug delivery technologies and development solutions. Catalent provides formulation, development, and manufacturing services for pharmaceuticals, biologics, and consumer health products.

Global leader in providing preclinical and clinical laboratory services. Charles River offers early-stage discovery, safety assessment, and clinical support services to pharmaceutical and biotech companies worldwide.

Global provider of outsourced development and commercialization services to the pharmaceutical, biotechnology, and medical device industries. ICON specializes in clinical research with operations across 53 countries.

A leading global contract research organization acquired by Thermo Fisher Scientific. PPD provides comprehensive clinical development services including laboratory, data management, and regulatory services.

Global biopharmaceutical services company providing clinical research, regulatory consulting, and market access services. Parexel has supported the development of many blockbuster drugs.

Japanese CRO subsidiary providing clinical monitoring, data management, and pharmacovigilance services specializing in small-to-mid-size pharma and biotech sponsors across Asia.

Global CDMO with 30+ years delivering development and manufacturing for biologics, cell therapies, viral vectors, and mRNA across US, European, and Asian facilities.

Contract research and manufacturing organization offering drug discovery, API synthesis, analytical development, and formulation services to global pharma and biotech.

Melbourne-founded CRO supporting small and mid-sized biotech companies across all clinical development stages including regulatory affairs, biometrics, and manufacturing scale-up.

Italian preclinical CRO providing GLP safety pharmacology, general and genetic toxicology, DMPK, and bioanalytical services from Nerviano (Milan) facilities.

Belgian mid-size CRO providing clinical trial management, medical monitoring, and pharmacovigilance services across the EU with particular strength in oncology and rare disease.

Budapest-based CRO providing full-service clinical trial management across Hungary and Central Europe, with capabilities in oncology, rare disease, and biosimilar clinical programs.

Clinical development and strategic resourcing organization providing full CRO services and functional service provider models to biopharma companies since 1994.

Leading IRB, IACUC, and consulting services provider for clinical and preclinical research, plus site management and performance optimization services.

Frankfurt-based specialty CRO focusing on endocrinology and oncology clinical development with strong European regulatory expertise.

US-based CRO providing full-service Phase I-IV clinical trial support for small and mid-size pharma and biotech with expertise in CNS, oncology, and infectious disease.

Mid-size global CRO under ALTEN Group formed by integrating Cmed and Larix, with deep oncology, rare disease, and cell/gene therapy clinical trial expertise across the US and Europe.

San Diego-based CDMO providing small and large molecule API manufacturing, oligonucleotide synthesis, and ADC conjugation services from pre-clinical through commercial scale.

Riyadh-based Saudi CRO providing clinical trial management, regulatory consulting, and pharmacovigilance services across the GCC region with SFDA regulatory expertise.

Specialist bioanalytical CRO combining LC-MS/MS, mass spectrometry imaging, and spatial biology platforms to support regulated discovery and clinical sample analysis.

Full-service CRO purpose-built for small and mid-size biotech, combining legacy of CATO Research, SMS Oncology, Pharm-Olam, and Nuventra into an integrated clinical development partner.

CDMO headquartered in Northern Ireland providing GMP API synthesis, drug product development, clinical trial supply manufacturing, and biomarker services across North America and Europe.

GLP-compliant preclinical CRO in Austin, Texas, offering 100+ validated xenograft efficacy models, IND-enabling toxicology, and RNAi therapeutic development services.

GLP-compliant bioanalytical CRO with 25+ years of LC-MS/MS and GC-MS/MS expertise supporting preclinical-to-clinical drug development from purpose-built facilities.

Full-service CRO integrating translational sciences, clinical pharmacology, bioanalysis, and regulatory strategy from preclinical through Phase IV development.

Full-service CRO based near FDA headquarters with 25+ years of regulatory and clinical trial expertise including adaptive designs, BE/BA studies, and pharmacovigilance.

Gene therapy and viral vector CDMO in Columbus, Ohio, with 20+ years of leadership and 500+ GMP drug substance batches produced for rare and ultra-rare disease programs.

UK nonclinical safety CRO founded by former AstraZeneca scientists, specializing in integrated toxicology and ion channel electrophysiology studies for regulatory drug safety assessment.

Hyderabad-headquartered integrated CRDMO providing CRO and CDMO solutions for small and large molecules to 450+ global pharma and biotech clients with 3,000+ professionals.

Belgian CDMO providing integrated drug substance and drug product development from early-phase API synthesis through formulation, analytical development, and GMP manufacturing.

German CRO and FSP provider delivering clinical trial management, pharmacovigilance, and medical information services across the DACH region and Central Europe.

French CRO providing Phase I-III clinical trial management and monitoring services across France and Western Europe, with expertise in rare disease and orphan drug development.

Australian full-service CRO providing Phase 1–3 clinical trial management with expertise in biotech-focused programs. Known for the Australian Clinical Trial Notification (CTN) regulatory pathway advantage.

Leading large molecule bioanalytical CRO specializing in ligand-binding assays, immunogenicity testing, flow cytometry, and biomarker analysis for biologics drug development.

Indian biopharmaceutical company providing biosimilar development, contract manufacturing, and clinical research services with GMP manufacturing facilities for biologics and biosimilars.

Israeli CRO specialising in clinical trial management, biostatistics, and regulatory affairs with expertise across Phase I-IV studies in oncology and rare diseases.

Miami-based full-service CRO specialising in complex and rare disease clinical trials with deep regulatory expertise for accelerated and breakthrough therapy designations.

Clinical research organization providing Phase I-III clinical trial management, monitoring, and regulatory services with a focus on small-to-mid-size biotech and specialty pharma sponsors.

South Korea's first CRO founded in 1997, providing comprehensive Phase I-IV clinical development solutions including regulatory affairs, data management, pharmacovigilance and medical translation.

Swiss CDMO providing integrated drug substance and drug product development services including API synthesis, process development, and highly potent compound manufacturing.

Regulatory affairs and clinical development consultancy providing full-service FDA/EMA submission support, pharmacovigilance, and clinical trial management for small pharma and biotech.

Independent early-phase CRO in the Netherlands specializing in first-in-human and Phase I trials using innovative biomarkers, with a purpose-built 54-bed clinical research unit adjacent to Leiden University Medical Center.

Japan's largest independent CRO providing end-to-end pharmaceutical development services including clinical operations, data management, regulatory affairs, and post-marketing surveillance across Asia.

Swiss independent Phase I and early-phase clinical CRO in Basel with a dedicated 24-bed clinical pharmacology unit, specializing in first-in-human studies for oncology, cardiovascular, and CNS compounds.

Swedish CRO with a 12-bed first-in-human research unit at Uppsala University Hospital, specializing in Phase I and Phase II trials with approximately five FIH studies annually.

Full-service mid-size CRO specialising in rare diseases, transplantation, nephrology, and immunology across Phase I-IV trials.

China-based global CRO providing full clinical development services from Phase I through IV with strong site networks across China, Korea, and Southeast Asia.

US-based site management organisation providing clinical trial site identification, feasibility, start-up, and monitoring services for pharma and biotech sponsors.

Biosimulation and regulatory science company providing model-informed drug development, regulatory science consulting, and software solutions for the pharmaceutical industry.

UK-headquartered global mid-size CRO (now part of LabCorp/Covance) with deep expertise in oncology, rare diseases, and paediatric clinical trials across 30+ countries.

Mid-size global CRO acquired by Labcorp providing clinical development services from Phase I through Phase IV with operations across Europe, Asia, and the Americas.

Global clinical trial technology and endpoint services company providing cardiac safety (ECG), respiratory, imaging, patient-reported outcomes, and clinical event adjudication for pharma and biotech sponsors.

Global full-service CRO founded in 1995 with strong Asia-Pacific and European presence, expanded via acquisition of CROMSOURCE for deeper European clinical operations.

Glasgow-founded, India-expanded full-service CRO providing clinical trial management, site management, and regulatory services across Asia-Pacific, Europe, and North America.

Australian full-service CRO focused on early-phase clinical trials in oncology, rare disease, and dermatology, leveraging Australia's Clinical Trial Notification scheme for faster trial start-up.

The only global full-service CRO focused exclusively on CNS drug development, with involvement in 22 FDA-approved CNS therapies across 13 indications.

Technology-enabled mid-size clinical CRO offering Phase I-IV development services with particular strength in oncology, rare disease, and CNS therapeutic areas.

Mid-size US CRO providing full-service Phase I-IV clinical trial management with expertise in oncology, rare disease, and CNS across 50+ countries.

New Jersey-based mid-size CRO and FSP provider offering clinical operations, data management, and regulatory services across 40+ countries.

GLP-compliant preclinical CRO specializing in toxicology, pathology, and ADME studies for pharmaceutical, biotech, and agrochemical clients with full necropsy and histopathology capabilities.

European CDMO network with 11 GMP facilities providing integrated API, drug product, and packaging services from pre-clinical through commercial scale including peptides, lipids, and injectables.

LabCorp Drug Development centre in Basel providing central laboratory services, companion diagnostics development, and specialised clinical testing for European pharma sponsors.

Specialty genomics laboratory providing biomarker services, companion diagnostics, and genomic profiling for clinical trials. Part of LabCorp Drug Development.

Labcorp Drug Development's UK preclinical facility providing GLP toxicology, safety pharmacology, and reproductive toxicology studies from Harrogate, North Yorkshire.

LabCorp Drug Development preclinical and toxicology centre in Madison, Wisconsin, providing GLP-compliant general and genetic toxicology, safety pharmacology, and reproductive toxicology studies.

Singapore-based global CRO consulting organisation assisting clients from clinical development through commercialisation with a focus on Asia-Pacific market access.

US-based CRO specializing in rare disease and pediatric clinical trials, providing end-to-end trial management with deep expertise in orphan drug development and regulatory strategy.

Full-service CRO with a dual-hub strategy across Eastern Europe and the Balkans, offering end-to-end clinical trial services for Phase I-IV studies with competitive patient recruitment timelines.

European mid-size CRO providing clinical trial monitoring, project management, and regulatory services across Europe with a model combining outsourced and insourced clinical operations.

CDMO offering integrated drug discovery, development, and manufacturing services including API production, drug product manufacturing, and analytical services from facilities in the US, Europe, and India.

Biostatistics-focused CRO and software company pioneering adaptive trial design, group sequential methods, and clinical trial simulation for pharma and biotech.

South Korean full-service CRO providing clinical development services from Phase I through post-marketing with bioanalytical capabilities and strong ties to Korean academic medical centers.

South Korea's largest clinical CRO and Tigermed subsidiary, delivering full-scope clinical services with 1,200+ successful projects across pharmaceuticals, biotech, and medical devices.

Global tech-enabled full-service CRO with strength in government-sponsored trials, infectious disease, vaccines, ophthalmology, and rare disease clinical development.

Global full-service CRO specializing in oncology, rare disease, and complex clinical trials across all development phases, with 2,900+ clinical research professionals operating in 100+ countries.

CDMO division of Eurofins providing process development, analytical development, and GMP manufacturing for biopharmaceutical products including monoclonal antibodies and recombinant proteins.

Global real-world evidence and outcomes research firm providing observational studies, health economics, market access, and regulatory evidence generation for pharma and biotech.

Paris-based European CRO providing clinical operations, pharmacovigilance, and regulatory affairs services across 40+ countries with particular strength in oncology and rare disease.

Specialty CRO providing GLP-compliant anatomic pathology, histotechnology, and immunohistochemistry services for pharma, biotech, and government preclinical research programs.

Top-tier biologics CDMO offering cell culture, microbial fermentation, and cell and gene therapy manufacturing across US sites supporting 128+ regulatory approvals.

Contract research organization spun off from Labcorp in 2023. Provides Phase 1–4 clinical development services, patient access solutions, and regulatory consulting globally.

Clinical trial arm of Frontage Laboratories providing Phase I-III services with integrated bioanalytical capabilities, bridging bioanalytical strength with full clinical execution.

German regulatory affairs consultancy providing EU regulatory strategy, marketing authorisation applications, and scientific advice for pharmaceutical and biotech sponsors.

Mexico City-based CRO and leading provider of decentralised clinical trial home visit services, patient recruitment, and community research site networks across 22 Latin American countries.

Life science regulatory and clinical development consultancy specialising in regulatory strategy, quality management, and organisational support for biotech and pharma.

Netherlands-based bioanalytical centre of excellence providing large-molecule bioanalysis, immunogenicity, and cell-based assay services for biologics and biosimilar programmes.

Specialised bioanalytical laboratory in New York providing large-molecule bioanalysis, immunogenicity testing, and ligand-binding assay development for biologics programmes.

ICON's Japanese operations providing full-service clinical development for pharmaceutical companies conducting trials in Japan and supporting PMDA regulatory submissions.

Australian CDMO providing API manufacturing, sterile fill-finish, and pharmaceutical development services from TGA-licensed and FDA-registered facilities in Melbourne.

Independent not-for-profit preclinical CRO offering full IND-enabling GLP toxicology programs, inhalation toxicology, and immunogenicity testing from the Illinois Institute of Technology campus.

Global clinical research and health data analytics company formed from the merger of IMS Health and Quintiles. Offers end-to-end clinical development, real-world evidence, and technology solutions.

IQVIA's Japanese subsidiary providing clinical operations, real-world data analytics, regulatory strategy and technology solutions with one of the largest clinical operations teams in Japan.

UAE's CRO headquartered under M42 Abu Dhabi, specialising in real-world evidence and comprehensive clinical trials across all therapeutic domains in the Gulf region.

Spanish CDMO specialising in oral solid dosage form development, hot-melt extrusion, spray drying, and GMP clinical supply manufacturing for early-phase programmes.

Retina-specialty CRO with offices across Latin America, Asia, and Australia supporting clinical trials in 18+ countries for ophthalmic and rare disease indications.

Canadian CRO providing Phase II-IV clinical trial management, real-world evidence studies, and health economics consulting with 30+ years of experience in respiratory, rheumatology, and dermatology.

Therapeutically specialized CRO focused on CNS, cardio-metabolic, renal, and rare disease trials, providing end-to-end CRO and SMO services across 39 countries with 220,000+ subjects enrolled.

US biologics CDMO providing cell line development, process development, cGMP manufacturing, and analytical services for monoclonal antibodies, recombinant proteins, and gene therapy products.

Pennsylvania-based bioanalytical CRO providing GLP-compliant LC-MS/MS and ligand-binding assay services for PK, immunogenicity, and biomarker analysis.

Istanbul-based Turkish CRO offering Phase I-IV clinical trials, bioequivalence studies, medical device trials, and electronic data capture services.

GLP/GMP-certified European bioanalytical and CMC CRO near Barcelona with four laboratories and 240 experts serving the full pharmaceutical product lifecycle since 2001.

Seoul-based full-service Korean CRO with 400 clinical trial experts and experience across 1,600+ studies including 180+ global multi-center trials.

Stockholm-based Nordic CRO providing clinical trial management, biostatistics, and regulatory support for Phase I-IV studies across Scandinavian countries with EMA and FDA regulatory experience.

Perth-based clinical trial site and CRO specializing in Phase 1–3 studies across multiple therapeutic areas. Located at the Harry Perkins Institute of Medical Research.

Japanese full-service CRO with global operations providing clinical development from early phase through post-marketing with deep oncology and CNS expertise across Asia, Europe, and the US.

Global CRO with nearly 1,000 employees covering 30+ countries, providing full-spectrum multilingual clinical development from early phase through post-approval in oncology and CNS.

Not-for-profit preclinical CRO with ABSL-3 capabilities and expertise in inhalation toxicology, pulmonary delivery, and infectious disease models from 100+ acre campus.

French clinical-stage gene therapy company and CRO specializing in CNS gene therapy development, providing clinical trial management for rare neurological diseases.

Leading MEA and Pakistan CRO with 140+ employees that has conducted 300+ clinical trials in 35 countries spanning the Middle East, Africa, Pakistan, and the Eurasian Economic Union.

Large preclinical CRO in Michigan acquired by Charles River Laboratories, providing GLP toxicology, safety pharmacology, and ADME studies in purpose-built facilities spanning over 800,000 sq ft.

Australian not-for-profit pharmaceutical company developing and registering medicines for neglected tropical diseases, providing regulatory and clinical development services for global health products.

Scientifically-driven, global, full-service clinical CRO providing Phase I-IV clinical development services. Medpace is known for its therapeutic expertise and operational efficiency.

Specialist CDMO for cell and gene therapy products offering GMP clinical and commercial manufacturing and development solutions for ATMPs from German, US, and Japanese facilities.

Boulder-based biologic discovery CRO integrating antibody discovery, protein engineering, function-first screening, and early developability assessment for complex biotherapeutics.

US-India hybrid CRO providing clinical trial management, regulatory affairs, pharmacovigilance, and medical writing with cost-effective offshore delivery from India.

Full-continuum preclinical CRO providing integrated in vitro and in vivo services including efficacy, toxicity, biodistribution, and product release studies in small and large animals.

Mid-size CRO acquired by IQVIA providing boutique-level clinical development services with deep therapeutic expertise in oncology, CNS, and rare disease for small-to-mid-size biotech sponsors.

Asia-Pacific specialist CRO providing full-service clinical development capabilities with deep expertise in the Asia-Pacific regulatory landscape.

Greater China operations of Australian CRO Novotech, providing full-service clinical trial management across mainland China, Hong Kong and Taiwan with NMPA submission expertise.

Leading Australian Phase 1 clinical trials unit operating in Melbourne, Brisbane, and Minneapolis. Specializes in first-in-human, oncology Phase 1, and healthy volunteer studies with rapid enrollment timelines.

Clinical pharmacology consulting firm specializing in PK/PD modeling, dose optimization, biosimilar development strategy, and regulatory science for pharmaceutical and biotech companies.

Specialized CDMO focused exclusively on sustained-release long-acting injectable formulation development, aseptic fill-finish, and lyophilization.

Regulatory consulting firm providing IND/NDA/BLA submission strategy, CMC consulting, and FDA interaction management for biotech and pharmaceutical sponsors.

Leading Central and Eastern European full-service CRO operating across 30+ countries with 510+ staff and 1,700+ completed studies, expanded through acquisitions of Crown CRO, SSS International, and MKS Research.

Cambridge-based specialty CRO focused on biostatistics, statistical programming, clinical data management, and regulatory submission support for pharma and biotech.

Swiss full-service CRO operating in 56 countries with 3,000 staff, specializing in pivotal Phase II-III clinical trials in oncology, hematology, multiple sclerosis, and rare diseases.

California-based bioanalytical CRO providing LC-MS/MS method development, validation, and sample analysis for PK/PD studies supporting IND and NDA submissions.

European full-service CRO formed by the 2024 merger of palleos healthcare and OCT Clinical, covering Western and Eastern Europe across 29 therapeutic areas from Wiesbaden, Germany.

Gene therapy-focused CDMO providing viral vector manufacturing for adeno-associated virus (AAV) gene therapies, acquired by Catalent to expand biologics capabilities.

Parexel's Indian operations providing clinical trial management, data management, biostatistics, and regulatory consulting for pharmaceutical companies conducting trials in India and South Asia.

Parexel's Japanese arm offering full-service clinical development, regulatory consulting and market access services with deep PMDA submission expertise.

Major global CDMO providing end-to-end pharmaceutical development and manufacturing services including drug substance, drug product, and commercial manufacturing under the Thermo Fisher Scientific umbrella.

Regulatory affairs and medical writing CRO providing IND/NDA/BLA preparation, regulatory strategy, and clinical documentation support for pharmaceutical and biotech companies.

Clinical data management and biometrics CRO specializing in biostatistics, statistical programming, and data management for small to mid-size pharmaceutical and biotech companies.

Mid-size full-service global CRO offering Phase I-IV clinical trial management with strong coverage across emerging markets in Africa, Latin America, and Eastern Europe.

Taipei-based drug development company and CRO specializing in oncology, running Phase I-III clinical trials for new cancer therapies and out-licensing proprietary pipeline assets.

Global regulatory affairs and drug development consulting firm providing IND/NDA/MAA filing support, clinical development strategy, and pharmacovigilance services.

European regulatory affairs and pharmacovigilance services provider offering end-to-end regulatory strategy, submission management, and post-authorization compliance for pharma and biotech companies.

Award-winning specialist biometrics CRO headquartered in London, providing biostatistics, statistical programming, data management, and analytics to global pharma, biotech, and device companies.

Global CDMO offering end-to-end pharmaceutical development and manufacturing including API synthesis, oral solid dose, sterile fill-finish, and antibody-drug conjugate manufacturing.

Durham-based CDMO using proprietary ARCUS genome editing technology to develop and manufacture next-generation allogeneic cell and gene therapy programs.

Specialty CRO focused on oncology and rare disease with 2,000+ professionals, known for biomarker-driven trial design, companion diagnostics, and translational research services.

Full-service global CRO providing clinical development services across all phases with deep expertise in CNS, rare disease, and cardiovascular therapeutic areas and strong site networks.

Global regulatory consulting, pharmacovigilance, and clinical research organization providing single-source regulatory strategy, compliance, and medical information services.

California-based clinical CRO providing Phase I-III trial management, monitoring, and project oversight for emerging biotech and small pharma sponsors.

Preclinical CRO specializing in CNS drug discovery using proprietary AI-powered behavioral phenotyping platforms for neurological and psychiatric disorders.

One of the world's largest data-focused biometrics CROs, providing biostatistics, statistical programming, clinical data management, and medical writing without conducting clinical operations.

Translational pharmaceutics CRO integrating drug substance, drug product, and clinical testing in a single facility. Specializes in formulation development with integrated Phase 1 studies.

US-based biomanufacturing CDMO founded in 2020 delivering end-to-end development and manufacturing for biologics, mRNA, and cell and gene therapy across a domestic facility network.

Specialist bioanalytical, biomarker, and analytical sciences CRO with 500+ experts providing FDA/EMA-inspection-ready regulated bioanalysis across the US, UK, and Australia.

Full-service CRO founded on biostatistics and data science excellence, supporting Phase I-IV trials across rare disease, immunology, and ophthalmology from Research Triangle Park.

Full-service contract research and consulting organization providing clinical trial management, biostatistics, data management, and regulatory services with particular expertise in rare disease and pediatrics.

Full-service CRO providing clinical research, biostatistics, data management, and regulatory services with particular expertise in ophthalmology, CNS, and rare disease.

Contract research organization providing discovery, preclinical, and development chemistry services including API synthesis, safety pharmacology, and medicinal chemistry.

Cell and gene therapy CDMO with purpose-built cGMP facilities in Edinburgh and Hopkinton, Massachusetts, supporting clinical and commercial advanced therapy programs.

National clinical research coordinating body in Singapore established by A*STAR and MOH, offering study design, project management, data management, and biostatistics to pharma and academic sponsors.

Global CDMO with integrated small molecule, biologics, and gene therapy manufacturing including proprietary viral vector platforms across the US, Europe, and Asia.

Japan's pioneering CRO founded in 1957 offering non-clinical safety evaluation including NHP studies, clinical Phase I-IV development, and a proprietary nasal drug delivery platform.

South Korean biosimilar developer and CDMO providing biologics development, manufacturing, and analytical services with a portfolio of approved biosimilar products across global markets.

Leading CDMO providing end-to-end biopharmaceutical manufacturing services including cell line development, process development, and commercial manufacturing at massive scale.

Slovak-founded global full-service CRO with integrated clinical supply chain and depot network spanning Europe, North America, LATAM, APAC, and South Africa.

Denmark-based GLP preclinical CRO offering safety pharmacology, general toxicology, reproductive toxicology, and ADME studies, known for rodent and non-rodent capabilities including minipig models.

Decentralized CRO enabling fully virtual and hybrid clinical trials through a proprietary Metasite platform, reducing site burden and improving patient access.

Swiss/German full-service CRO providing Phase I-IV clinical trial management, regulatory consulting, and medical writing with offices across Germany, Austria, and Switzerland.

Full-service boutique CRO with a purpose-built MHRA-accredited Phase I unit in South Wales. Specializes in early-phase clinical pharmacology, oncology, rare diseases, and respiratory conditions through to Phase III.

Full-service clinical CRO headquartered in Oslo with a distinctive co-investment business model and offices across Scandinavia, UK, Germany, and Poland, specializing in oncology and rare diseases.

Spain-based full-service European CRO specialising in Phase I-IV clinical trial management across EU member states with expertise in regulatory affairs and site monitoring.

Independent Australian full-service CRO specializing in pharmaceutical, medical device and biotechnology clinical trials, award-winning APAC CRO of the Year.

Munich-based specialty CRO providing biostatistics, statistical programming, and data science services for pharmaceutical, biotech, and medical device clinical trials.

Hyderabad-headquartered pharmaceutical CRO with dedicated clinical trials division providing drug discovery, early-phase clinical, and regulatory support with strong CNS expertise.

Consulting arm of Syneos Health providing commercial and regulatory advisory, launch planning, and market access strategy for pharmaceutical and biotech clients.

California-based mid-size CRO providing full-service Phase I-III clinical trial management with deep expertise in oncology, rare disease, and CNS for emerging biotech.

Mid-size CRO specializing in clinical development for small and emerging biotech companies. Now part of Allucent, offering Phase 1–3 trial management and regulatory consulting.

Mid-size global CRO with nearly 700 professionals across 50 countries, specializing in oncology, rare disease, and complex clinical programs with particular strength in dermatology and CNS.

South Korean genomics and CRO company providing next-generation sequencing, genomic analysis, and precision medicine research services alongside clinical biomarker and pharmacogenomics programs.

China's largest independent CRO providing comprehensive clinical development services from preclinical through post-marketing with operations across China, Asia, and globally.

Oncology-focused CRO founded on the Mayo Clinic campus offering preclinical-to-clinical oncology development with PDX models, flow cytometry, and Phase I/II trial management.

Medical writing and regulatory consulting CRO providing clinical study reports, investigator brochures, CTD modules, and submission documents for FDA and EMA regulatory filings.

Specialized biometrics and regulatory CRO providing biostatistics, data management, medical writing, and regulatory strategy for pharmaceutical and biotech companies seeking FDA and EMA approvals.

Leading provider of clinical trial solutions including IRB/ethics review, site performance optimization, data analytics, and clinical trial management services for the pharmaceutical industry.

Mid-size global CRO providing Phase I-IV clinical development services with expertise in CNS, cardiovascular, and metabolic disease therapeutic areas.

Mid-size full-service global CRO offering integrated bioanalytical lab services alongside Phase I-IV clinical trial management with a focus on CNS, cardiovascular, and rare disease.

WuXi AppTec's cell and gene therapy division providing GMP viral vector manufacturing, cell therapy manufacturing, and plasmid DNA production from US and China facilities.

Global biologics CDMO providing end-to-end solutions for biologics drug development and manufacturing including monoclonal antibodies, bispecific antibodies, ADCs, and cell and gene therapies.

Clinical division of WuXi AppTec providing end-to-end Phase I-IV clinical trial services across China and Asia with expertise in NMPA, FDA and EMA regulatory submissions.

Lagos-based pioneer indigenous African CRO delivering Phase I-IV clinical trials with a focus on vaccines, neglected tropical diseases, oncology, and rare diseases across Sub-Saharan Africa.

Barcelona-based preclinical CRO pioneering zebrafish-based platforms for efficacy testing, safety pharmacology, and toxicity assessment of pharmaceutical and chemical compounds.

Physician-led Australian CRO offering full-spectrum clinical and non-clinical services with AI-driven operating model across Phase I-III for innovative biotechs.

Independent pharmaceutical development services company in Basel providing drug formulation development, analytical development, and stability testing for injectable and biopharmaceutical products.